These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 32168760)

  • 1. Affibody Molecules as Targeting Vectors for PET Imaging.
    Tolmachev V; Orlova A
    Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32168760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the first
    Honarvar H; Müller C; Cohrs S; Haller S; Westerlund K; Karlström AE; van der Meulen NP; Schibli R; Tolmachev V
    Nucl Med Biol; 2017 Feb; 45():15-21. PubMed ID: 27837664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PET Imaging of HER2-Positive Tumors with Cu-64-Labeled Affibody Molecules.
    Qi S; Hoppmann S; Xu Y; Cheng Z
    Mol Imaging Biol; 2019 Oct; 21(5):907-916. PubMed ID: 30617730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imaging of human epidermal growth factor receptor type 2 expression with 18F-labeled affibody molecule ZHER2:2395 in a mouse model for ovarian cancer.
    Heskamp S; Laverman P; Rosik D; Boschetti F; van der Graaf WT; Oyen WJ; van Laarhoven HW; Tolmachev V; Boerman OC
    J Nucl Med; 2012 Jan; 53(1):146-53. PubMed ID: 22173842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular design and optimization of 99mTc-labeled recombinant affibody molecules improves their biodistribution and imaging properties.
    Wållberg H; Orlova A; Altai M; Hosseinimehr SJ; Widström C; Malmberg J; Ståhl S; Tolmachev V
    J Nucl Med; 2011 Mar; 52(3):461-9. PubMed ID: 21321280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Order of amino acids in C-terminal cysteine-containing peptide-based chelators influences cellular processing and biodistribution of 99mTc-labeled recombinant Affibody molecules.
    Altai M; Wållberg H; Orlova A; Rosestedt M; Hosseinimehr SJ; Tolmachev V; Ståhl S
    Amino Acids; 2012 May; 42(5):1975-85. PubMed ID: 21573874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incorporation of a triglutamyl spacer improves the biodistribution of synthetic affibody molecules radiofluorinated at the N-terminus via oxime formation with (18)F-4-fluorobenzaldehyde.
    Rosik D; Thibblin A; Antoni G; Honarvar H; Strand J; Selvaraju RK; Altai M; Orlova A; Eriksson Karlström A; Tolmachev V
    Bioconjug Chem; 2014 Jan; 25(1):82-92. PubMed ID: 24344772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of nuclides and chelators on imaging using affibody molecules: comparative evaluation of recombinant affibody molecules site-specifically labeled with ⁶⁸Ga and ¹¹¹In via maleimido derivatives of DOTA and NODAGA.
    Altai M; Strand J; Rosik D; Selvaraju RK; Eriksson Karlström A; Orlova A; Tolmachev V
    Bioconjug Chem; 2013 Jun; 24(6):1102-9. PubMed ID: 23705574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radionuclide molecular imaging using Affibody molecules.
    Ahlgren S; Tolmachev V
    Curr Pharm Biotechnol; 2010 Sep; 11(6):581-9. PubMed ID: 20497119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of DOTA chelator position on biodistribution and targeting properties of (111)In-labeled synthetic anti-HER2 affibody molecules.
    Perols A; Honarvar H; Strand J; Selvaraju R; Orlova A; Karlström AE; Tolmachev V
    Bioconjug Chem; 2012 Aug; 23(8):1661-70. PubMed ID: 22768790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increasing the Net Negative Charge by Replacement of DOTA Chelator with DOTAGA Improves the Biodistribution of Radiolabeled Second-Generation Synthetic Affibody Molecules.
    Westerlund K; Honarvar H; Norrström E; Strand J; Mitran B; Orlova A; Eriksson Karlström A; Tolmachev V
    Mol Pharm; 2016 May; 13(5):1668-78. PubMed ID: 27010700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Affibody molecules: potential for in vivo imaging of molecular targets for cancer therapy.
    Tolmachev V; Orlova A; Nilsson FY; Feldwisch J; Wennborg A; Abrahmsén L
    Expert Opin Biol Ther; 2007 Apr; 7(4):555-68. PubMed ID: 17373906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo and in vitro studies on renal uptake of radiolabeled affibody molecules for imaging of HER2 expression in tumors.
    Altai M; Varasteh Z; Andersson K; Eek A; Boerman O; Orlova A
    Cancer Biother Radiopharm; 2013 Apr; 28(3):187-95. PubMed ID: 23461385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo evaluation of cysteine-based chelators for attachment of 99mTc to tumor-targeting Affibody molecules.
    Tran T; Engfeldt T; Orlova A; Widström C; Bruskin A; Tolmachev V; Karlström AE
    Bioconjug Chem; 2007; 18(2):549-58. PubMed ID: 17330952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Position for site-specific attachment of a DOTA chelator to synthetic affibody molecules has a different influence on the targeting properties of 68Ga- compared to 111in-labeled conjugates.
    Honarvar H; Strand J; Perols A; Orlova A; Selvaraju RK; Eriksson Karlström A; Tolmachev V
    Mol Imaging; 2014; 13():. PubMed ID: 25249017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Site-Specific Radioiodination of HER2-Targeting Affibody Molecules using 4-Iodophenethylmaleimide Decreases Renal Uptake of Radioactivity.
    Strand J; Nordeman P; Honarvar H; Altai M; Orlova A; Larhed M; Tolmachev V
    ChemistryOpen; 2015 Apr; 4(2):174-82. PubMed ID: 25969816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor targeting using affibody molecules: interplay of affinity, target expression level, and binding site composition.
    Tolmachev V; Tran TA; Rosik D; Sjöberg A; Abrahmsén L; Orlova A
    J Nucl Med; 2012 Jun; 53(6):953-60. PubMed ID: 22586147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine.
    Ahlgren S; Wållberg H; Tran TA; Widström C; Hjertman M; Abrahmsén L; Berndorff D; Dinkelborg LM; Cyr JE; Feldwisch J; Orlova A; Tolmachev V
    J Nucl Med; 2009 May; 50(5):781-9. PubMed ID: 19372467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Site-specific radiometal labeling and improved biodistribution using ABY-027, a novel HER2-targeting affibody molecule-albumin-binding domain fusion protein.
    Orlova A; Jonsson A; Rosik D; Lundqvist H; Lindborg M; Abrahmsen L; Ekblad C; Frejd FY; Tolmachev V
    J Nucl Med; 2013 Jun; 54(6):961-8. PubMed ID: 23528382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Three methods for 18F labeling of the HER2-binding affibody molecule Z(HER2:2891) including preclinical assessment.
    Glaser M; Iveson P; Hoppmann S; Indrevoll B; Wilson A; Arukwe J; Danikas A; Bhalla R; Hiscock D
    J Nucl Med; 2013 Nov; 54(11):1981-8. PubMed ID: 24115530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.